Active Biotech AB Year-end report January - December 2016
February 16 2017 - 2:30AM
Laquinimod
-
The clinical trials CONCERTO, ARPEGGIO and
LEGATO-HD are progressing according to plan
-
The study results from the pivotal clinical
Phase 3 CONCERTO trial in relapsing remitting multiple sclerosis
(RRMS) are expected in the first half of 2017
-
The study results from the clinical Phase 2
ARPEGGIO trial, evaluating laquinimod for the treatment of primary
progressive multiple sclerosis (PPMS), are expected in the second
half of 2017
-
Orphan Drug Designation granted in the US by the
FDA ("US Food and Drug Administration") for laquinimod for
the treatment of Huntington's disease
ANYARA
Tasquinimod, Paquinimod and
SILC
-
Out-licensing activities are continuing
-
The European Patent Office has granted a patent
application covering tasquinimod for use in the treatment of
multiple myeloma
-
Product patent for SILC substances granted by
the European Patent Office
New share issue
Financial
summary
SEK M |
Oct -
Dec |
Jan
- Dec |
|
2016 |
2015 |
2016 |
2015 |
Net
sales |
7.1 |
5.0 |
19.0 |
16.3 |
Operating
loss |
-13.5 |
-28.2 |
-55.1 |
-177.9 |
Loss for
the period |
-14.8 |
-40.8 |
-59.6 |
-193.5 |
Loss per
share, before and after dilution (SEK) |
-0.16 |
-0.45 |
-0.65 |
-2.13 |
Cash and
cash equivalents |
|
|
77.7 |
103.6 |
|
|
|
|
|
For further
information, please contact:
Tomas
Leanderson, President and CEO
Tel: +46 (0) 46 19 20 95
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
|
Active
Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
|
The report is also available at
www.activebiotech.com.
Active Biotech AB Year-end report
January – December 2016
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Apr 2023 to Apr 2024